AstraZeneca(US:AZN) Xin Lang Cai Jing·2025-11-05 13:47Core Insights - AstraZeneca showcased its commitment to expanding production in China at the 8th China International Import Expo, highlighting its latest achievements in sustainable development and innovative drug offerings [1][2] - The company signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone, committing to an additional investment of approximately $136 million to enhance production capacity [1] - The expansion aims to increase the production of inhalation aerosol products to better meet the treatment needs of patients with respiratory diseases such as asthma and COPD [1] Investment and Production Expansion - The Qingdao facility expansion will utilize energy-saving technologies to achieve near-zero carbon operations [1] - AstraZeneca's Wuxi facility has achieved 100% renewable energy usage and is recognized for implementing innovative clean heating solutions, receiving carbon neutrality certification [1] - The Taizhou facility has reduced carbon emissions by 97.5% compared to 2015 levels, with the Qingdao facility expected to achieve similar near-zero carbon operations upon completion [1] Innovative Drug Offerings - At the expo, AstraZeneca presented two newly approved oncology drugs in China: QianKede® (Capecitabine Tablets) and Dazhuoyou® (Darbepoetin Alfa Injection) [2] - The company also showcased innovative therapies for various new disease areas [2]